Corbus brags about another PhII success for its lead drug, but shares slide early
Corbus Pharmaceuticals has plucked out some positive data from its mid-stage cystic fibrosis study. But it didn’t help its stock price this morning.
While the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.